Monte Rosa Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Monte Rosa Therapeutics reported significant progress in its molecular glue degrader pipeline, including positive clinical data for MRT-2359 and MRT-8102, and strengthened its financial position with a $323.8 million capital raise.
NASDAQ
10-K: Monte Rosa Therapeutics Announces Promising Progress in 2024, Licenses VAV1 Program to Novartis
Monte Rosa Therapeutics reports financial results for 2024, highlights clinical progress, and enters a strategic licensing agreement with Novartis for its VAV1-directed MGD program.
NASDAQ
Monte Rosa Therapeutics' 10-K filing outlines its capital structure, including common and preferred stock, pre-funded warrants, and various anti-takeover provisions.